<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770575</url>
  </required_header>
  <id_info>
    <org_study_id>ATS K015</org_study_id>
    <secondary_id>2004-004463-30</secondary_id>
    <secondary_id>D-PIO-106</secondary_id>
    <secondary_id>U1111-1115-9124</secondary_id>
    <nct_id>NCT00770575</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease</brief_title>
  <official_title>Double Blinded Study of the Effects of Pioglitazone in Combination With Atorvastatin in Comparison to Atorvastatin Treatment Alone on Intima-Media Thickness in Patients at Risk for Vascular Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and&#xD;
      atorvastatin combination therapy compared to atorvastatin monotherapy in patients at risk for&#xD;
      cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carotid intima-media thickness is a well described surrogate marker for cardiovascular risk.&#xD;
      A thickened carotid intima media layer correlates not only with the presence of&#xD;
      cardiovascular risk factors but also the risk of future macrovascular events such as&#xD;
      myocardial infarction and stroke. The interventional approach of cardiovascular risk factors&#xD;
      with angiotensin converting enzyme system blockers, calcium antagonists or beta blockers can&#xD;
      result in reduction of progression or even net regression of carotid intima-media thickness.&#xD;
      The most potent agents, however, are statins which have consistently shown effects on carotid&#xD;
      intima-media thickness in patients with hypercholesterolemia and/or atherosclerotic disease.&#xD;
&#xD;
      Peroxisome proliferator activator receptor-gamma activation by thiazolidinediones is a&#xD;
      promising new approach which reduces insulin resistance and improves lipid profile. In&#xD;
      addition to their metabolic activities, peroxisome proliferator activator receptor-gamma&#xD;
      activators were shown to exert anti-inflammatory effects, to improve endothelial function and&#xD;
      to inhibit atherogenesis in diabetic and in non-diabetic atherosclerosis-prone animal models.&#xD;
      Treatment with peroxisome proliferator activator receptor-gamma agonists have shown to reduce&#xD;
      arterial pressure and carotid intima-media thickness in diabetic and non-diabetic patients at&#xD;
      risk for cardiovascular disease.&#xD;
&#xD;
      The aim of this study is to evaluate the effect of Pioglitazone in addition to Atorvastatin&#xD;
      compared to Atorvastatin alone on vascular risk markers and intima-media thickness in&#xD;
      patients with elevated risk for cardiovascular disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the intima-media thickness of the common carotid artery.</measure>
    <time_frame>Week 24.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the intima-media thickness of the internal carotid artery.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the intima-media thickness of the carotid bulbus.</measure>
    <time_frame>Week 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Efficacy Laboratory findings (Interleukin-6, high sensitive C reactive peptide and monocyte chemotactic protein-1)</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Efficacy Laboratory findings (matrix metalloproteinase-9, soluble CD40 Ligand, P-Selectin, soluble intracellular adhesion molecule 1 and soluble vascular cell adhesion molecule 1).</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Efficacy Laboratory findings (adiponectin, tissue plasminogen activator, Plasma glucose, Insulin and Intact proinsulin).</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Efficacy Laboratory findings (blood lipids (total cholesterol, high density lipoprotein, triglycerides) and low density lipoprotein-subfractions).</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glycosylated Hemoglobin.</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Beta cell function (Homeostatic Model Assessment - beta cell response Score).</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Insulin sensitivity using the Homeostatic Model Assessment - Sensitivity Score).</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Microcirculation assessment.</measure>
    <time_frame>Week: 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse wave velocity.</measure>
    <time_frame>Weeks: 12 and 24.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg to 40 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and atorvastatin</intervention_name>
    <description>Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:&#xD;
Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.</description>
    <arm_group_label>Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD</arm_group_label>
    <other_name>ACTOS®</other_name>
    <other_name>AD4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to&#xD;
Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.</description>
    <arm_group_label>Atorvastatin 20mg to 40 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intima-media thickness of Common Carotid Artery greater than or equal to 0.8 mm (at&#xD;
             least on one side).&#xD;
&#xD;
          -  Increased cardiovascular risk defined as one or more of the following:&#xD;
&#xD;
               -  medical history of infarction&#xD;
&#xD;
               -  coronary angiography with proven cardiovascular disease&#xD;
&#xD;
               -  instable Angina pectoris&#xD;
&#xD;
               -  duplex-sonography of cervical or leg vessels with proven atherosclerotic vascular&#xD;
                  alterations&#xD;
&#xD;
               -  electrocardiogram with ischemia&#xD;
&#xD;
               -  stroke&#xD;
&#xD;
               -  transient ischemic attack&#xD;
&#xD;
               -  peripheral arterial occlusion&#xD;
&#xD;
               -  vessel surgery&#xD;
&#xD;
               -  hypertension (RR greater than 140/90)&#xD;
&#xD;
               -  antihypertensives&#xD;
&#xD;
               -  high density lipoprotein less than 40 mg/dl.&#xD;
&#xD;
          -  Body mass index greater than or equal to 25 kg/m2.&#xD;
&#xD;
          -  Females of childbearing potential who are sexually active must agree to use adequate&#xD;
             contraception, and can neither be pregnant nor lactating from Screening throughout the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of overt type-2-diabetes according to the World Health Organization criteria.&#xD;
&#xD;
          -  History of type-1-diabetes.&#xD;
&#xD;
          -  History of more than one unexplained hypoglycemic episode within the last 6 months.&#xD;
&#xD;
          -  Statin therapy within the last 4 weeks.&#xD;
&#xD;
          -  Anamnestic history of hypersensitivity to the study drugs or to drugs with similar&#xD;
             chemical structures.&#xD;
&#xD;
          -  History of severe or multiple allergies.&#xD;
&#xD;
          -  Treatment with any other investigational drug within 3 months before trial entry.&#xD;
&#xD;
          -  Progressive fatal disease.&#xD;
&#xD;
          -  Myopathy.&#xD;
&#xD;
          -  Drug or alcohol abuse within the last 5 years.&#xD;
&#xD;
          -  Smoker defined as patient with evidence or history of tobacco or nicotine use within&#xD;
             the last 6 months before the screening visit.&#xD;
&#xD;
          -  A history of heart failure (New York Heart Association stage II - IV) or significant&#xD;
             respiratory, gastrointestinal, hepatic (glutamate-pyruvate-transaminase time greater&#xD;
             than 2.5 times the normal reference range), renal (creatinine greater than 2.0 mg/dl)&#xD;
             or hematological disease.&#xD;
&#xD;
          -  Blood donation within the last 30 days.&#xD;
&#xD;
          -  Is required to take or intends to continue taking any disallowed medication, any&#xD;
             prescription medication, herbal treatment or over-the counter medication that may&#xD;
             interfere with evaluation of the study medication, including:&#xD;
&#xD;
               -  ciclosporin&#xD;
&#xD;
               -  erythromycin&#xD;
&#xD;
               -  clarithromycin&#xD;
&#xD;
               -  itraconazole&#xD;
&#xD;
               -  ketoconazole&#xD;
&#xD;
               -  nefazodone&#xD;
&#xD;
               -  niacin&#xD;
&#xD;
               -  gemfibrozil and other fibrates&#xD;
&#xD;
               -  HIV-Protease-Inhibitors&#xD;
&#xD;
          -  Pre-treatment with thiazolidinediones within 3 months before trial entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Research/Licensing/New Products</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Pharma Gmbh, Aachen (Germany)</affiliation>
  </overall_official>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ACTOSPI</url>
    <description>ACTOS® Package Insert</description>
  </link>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Takeda Pharma GmbH, Aachen (Germany)</organization>
  </responsible_party>
  <keyword>Biological Markers</keyword>
  <keyword>Biochemical Markers</keyword>
  <keyword>Carotid Artery, Internal</keyword>
  <keyword>Carotid Artery, Common</keyword>
  <keyword>Marker, Surrogate</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

